DNA probe technology: implications for service planning in Britain
- PMID: 1424242
- DOI: 10.1111/j.1399-0004.1992.tb03235.x
DNA probe technology: implications for service planning in Britain
Abstract
For certain genetic conditions DNA testing identifies carriers and determines the risk status of foetuses, thus helping parents to make more informed prenatal decisions. Data, collected from three genetic centres in England and Wales from August 1986 to July 1990, are used to describe trends in demand for DNA testing, the impact of DNA tests on carrier risk assessment, and the use of DNA tests in relation to pregnancy outcome. Altogether the data include 23,388 subjects and 681 pregnancies in 8738 families divided into five cohorts by year of entry and referral. The most frequent gene disorders referred to the genetic centres are currently being tested or will soon be tested. For these disorders the initial high level of activity has declined and may have reached steady state. Demand for DNA services is high for cystic fibrosis and Duchenne muscular dystrophy, intermediate for Huntington's disease, and low for adult polycystic kidney disease, phenylketonuria and tuberous sclerosis. Based on these findings we suggest that demand for DNA tests will be high in serious, untreatable and slow progressing conditions with early onset; intermediate for conditions affecting intellect and neurological integrity with later onset; and low for treatable, late-onset conditions, or those for which there is evidence of heterogeneity, and variable penetrance. It would be helpful to assess the extent to which this view of demand is confirmed when the new disorders being DNA tested are considered and for the pattern of activity of DNA testing for some types of cancer. Since no DNA centre could offer a fully comprehensive testing service, it is recommended that a structure is created to audit overall activity, assist in policy formulation, and influence supraregional service organisation, in order that the spread of DNA services be planned as effectively as possible. This structure would facilitate monitoring of the evolution of contract specifications agreed by commissioners and providers on a regional basis.
Similar articles
-
Demand for DNA probe testing in three genetic centres in Britain (August 1986 to July 1987).J Med Genet. 1989 Apr;26(4):226-36. doi: 10.1136/jmg.26.4.226. J Med Genet. 1989. PMID: 2716033 Free PMC article.
-
The resource implications and service outcomes of genetic services in the context of DNA technology.Health Policy. 1994 Jan 15;26(3):171-90. doi: 10.1016/0168-8510(94)90038-8. Health Policy. 1994. PMID: 10133130 Review.
-
Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing.J Obstet Gynaecol Can. 2016 Aug;38(8):742-762.e3. doi: 10.1016/j.jogc.2016.06.008. J Obstet Gynaecol Can. 2016. PMID: 27638987
-
Molecular genetics in clinical practice: evolution of a DNA diagnostic service.BMJ. 1988 Oct 1;297(6652):843-6. doi: 10.1136/bmj.297.6652.843. BMJ. 1988. PMID: 2972330 Free PMC article.
-
Carrier screening for thalassemia and hemoglobinopathies in Canada.J Obstet Gynaecol Can. 2008 Oct;30(10):950-959. doi: 10.1016/S1701-2163(16)32975-9. J Obstet Gynaecol Can. 2008. PMID: 19038079 Review. English, French.
Cited by
-
Clinical genetics in neurological disease.J Neurol Neurosurg Psychiatry. 1994 Jan;57(1):7-15. doi: 10.1136/jnnp.57.1.7. J Neurol Neurosurg Psychiatry. 1994. PMID: 8301308 Free PMC article. Review. No abstract available.
-
An overview of clinical molecular genetics.Mol Biotechnol. 1997 Oct;8(2):95-104. doi: 10.1007/BF02752254. Mol Biotechnol. 1997. PMID: 9406180 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical